Effect of PPARγ ligands on cell number of prostate cell lines at day 5. Cells were treated with control (0.2% DMSO), troglitazone (100 μM; TGZ), ciglitazone (40 μM; CGZ), rosiglitazone (10 μM; RGZ), pioglitazone (20 μM; PGZ) and 15-deoxy-prostaglandin J2 (5.6 and 10 μM; 15dPGJ2) in the presence or absence of antagonist GW9662 (10 μM) at day 0. A, DU145 cells; B, PC-3 cells; C, LNCaP cells Values are mean ± SEM of two experiments performed in triplicate expressed as percent control. No significant differences were detected following GW9662 treatment for any agent. Statistical significance compared to control * P < 0.01, #
P < 0.05 (ANOVA followed by Dunnett post test).